Stock Notification: Sandomigran, pizotifen 0.5 mg (as maleate) tablet

Sandomigran, pizotifen 0.5 mg (as maleate) tablet AUST R 69608

In July 2015, AFT Pharmaceuticals Pty Ltd took over the sponsorship of Sandomigran tablets from Novartis Pharmaceuticals Pty Ltd.

AFT Pharmaceuticals Pty Ltd are currently out of stock of this product at their warehouse. This situation has arisen as a consequence of the change of sponsorship affecting production of the finished product.

It is our understanding that wholesalers are typically holding between 4 and 6 weeks stock of the product which we are hoping this stock holding will prevent unavailability of the product to patients.

We are arranging to take delivery of 15,000 units of stock which will expire in June 2016. This stock is expected to be available for distribution by late November 2015. In addition, AFT Pharmaceuticals have an application with the TGA which when approved will allow for a further 78,000 units to become available.

It is anticipated that normal production and subsequent supply of the product will re-commence from February 2016.

We thank you for your understanding of the situation.

July 23, 2026

Pitt St Research initiates coverage on AFT Pharmaceuticals

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that Pitt St Research has initiated coverage on AFT Pharmaceuticals Ltd….

Read More

May 21, 2026

AFT delivers double digit revenue growth and record earnings

Operating profit or $24.4 million ahead of the guidance range….

Read More

May 18, 2026

AFT Pharmaceuticals names Stuart Houliston CFO

AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company, today advises that Stuart Houliston will commence …

Read More